SCHEMBL25791157

SCHEMBL25791157

Cc1ccc2[nH]ncc2c1CCN

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT2 P31751 2/20 0.43
▸ HTR6 P50406 4/20 0.42
▸ HTR1D P28221 2/20 0.42
▸ TDP1 Q9NUW8 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ HTR7 P34969 1/20 0.42
▸ HTR3A P46098 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ IDO1 P14902 1/20 0.38
▸ MAP4K1 Q92918 1/20 0.36
▸ WEE1 P30291 1/20 0.36
▸ PKMYT1 Q99640 1/20 0.36
▸ NOS1 P29475 3/20 0.36
▸ AXL P30530 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21986879 0.86 NOS1 (0.42) AKT2IDO1MAP4K1WEE1PKMYT1
SCHEMBL20850537 0.81 CDK2 (0.43) IDO1MAP4K1NOS1AXLCDK2
SCHEMBL21986864 0.79 IDO1 (0.40) IDO1MAP4K1WEE1PKMYT1NOS1
SCHEMBL22864052 0.77 JAK2 (0.38) IDO1MAP4K1NOS1AXLJAK2
SCHEMBL22757498 0.74 ESR2 (0.38) IDO1MAP4K1NOS1AXLCDK2
SCHEMBL10838630 0.73 ROCK2 (0.39) IDO1MAP4K1NOS1AXLROCK2
SCHEMBL3534803 0.73 MAPT (0.52) TDP1HSD17B10IDO1MAP4K1WEE1
SCHEMBL8404436 0.72 IDO1 (0.46) IDO1NOS1AXLMAPTJAK2
SCHEMBL21986783 0.72 IDO1 (0.37) IDO1MAP4K1NOS1AXLCDK2
SCHEMBL16647168 0.69 IDO1 (0.47) IDO1NOS1AXLMAPTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023114733-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. (US) 2023-06-22 — — WO disclosed
Send feedback